1. Morimoto A, Nakazawa Y, Ishii E. 2016; Hemophagocytic lymphohistiocytosis: pathogenesis, diagnosis, and management. Pediatr Int. 58:817–25. DOI:
10.1111/ped.13064. PMID:
27289085.
Article
2. Carter SJ, Tattersall RS, Ramanan AV. 2019; Macrophage activation syndrome in adults: recent advances in pathophysiology, diagnosis and treatment. Rheumatology (Oxford). 58:5–17. DOI:
10.1093/rheumatology/key006. PMID:
29481673.
Article
3. Henter JI, Horne A, Aricó M, Egeler RM, Filipovich AH, Imashuku S, et al. 2007; HLH-2004: diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer. 48:124–31. DOI:
10.1002/pbc.21039. PMID:
16937360.
Article
5. Ahmed A, Merrill SA, Alsawah F, Bockenstedt P, Campagnaro E, Devata S, et al. 2019; Ruxolitinib in adult patients with secondary haemophagocytic lymphohistiocytosis: an open-label, single-centre, pilot trial. Lancet Haematol. 6:e630–7. DOI:
10.1016/S2352-3026(19)30156-5. PMID:
31537486.
Article
6. Das R, Guan P, Sprague L, Verbist K, Tedrick P, An QA, et al. 2016; Janus kinase inhibition lessens inflammation and ameliorates disease in murine models of hemophagocytic lymphohistiocytosis. Blood. 127:1666–75. DOI:
10.1182/blood-2015-12-684399. PMID:
26825707. PMCID:
PMC4817310.
Article
9. Fardet L, Galicier L, Lambotte O, Marzac C, Aumont C, Chahwan D, et al. 2014; Development and validation of the HScore, a score for the diagnosis of reactive hemophagocytic syndrome. Arthritis Rheumatol. 66:2613–20. DOI:
10.1002/art.38690. PMID:
24782338.
Article
10. Gavand PE, Serio I, Arnaud L, Costedoat-Chalumeau N, Carvelli J, Dossier A, et al. 2017; Clinical spectrum and therapeutic management of systemic lupus erythematosus-associated macrophage activation syndrome: a study of 103 episodes in 89 adult patients. Autoimmun Rev. 16:743–9. DOI:
10.1016/j.autrev.2017.05.010. PMID:
28483541.
Article
11. Nam SH, Ahn SM, Oh JS, Hong S, Lee CK, Yoo B, et al. 2022; Macrophage activation syndrome in rheumatic disease: clinical characteristics and prognosis of 20 adult patients. PLoS One. 17:e0267715. DOI:
10.1371/journal.pone.0267715. PMID:
35522672. PMCID:
PMC9075640.
Article
12. Wafa A, Hicham H, Naoufal R, Hajar K, Rachid R, Souad B, et al. 2022; Clinical spectrum and therapeutic management of systemic lupus erythematosus-associated macrophage activation syndrome: a study of 20 Moroccan adult patients. Clin Rheumatol. 41:2021–33. DOI:
10.1007/s10067-022-06055-9. PMID:
35179662.
Article
14. Rumi E, Sant'Antonio E, Cavalloni C, Comolli G, Ferretti VV, Cassaniti I, et al. 2020; Impaired virus-specific T cell responses in patients with myeloproliferative neoplasms treated with ruxolitinib. Hematol Oncol. 38:554–9. DOI:
10.1002/hon.2769. PMID:
32583904.
Article
15. Abedin S, McKenna E, Chhabra S, Pasquini M, Shah NN, Jerkins J, et al. 2019; Efficacy, toxicity, and infectious complications in ruxolitinib-treated patients with corticosteroid-refractory graft-versus-host disease after hematopoietic cell transplantation. Biol Blood Marrow Transplant. 25:1689–94. DOI:
10.1016/j.bbmt.2019.04.003. PMID:
30965140.
Article